🧬 Aging Wiki

smac-diablo

Properties1
aliasesSMAC, DIABLO, second mitochondria-derived activator of caspases, direct IAP-binding protein with low pI, SMAC/DIABLO

9 min read

SMAC/DIABLO

A mitochondrial IMS protein that promotes apoptosis by antagonizing XIAP and other IAP-family proteins upon release to the cytosol during MOMP. SMAC/DIABLO is the molecular explanation for how bax/bak-driven MOMP not only releases cytochrome-c to form the apoptosome, but simultaneously de-inhibits caspase-9 and caspase-3 from IAP restraint.

Identity

  • UniProt: Q9NR28 (DBLOH_HUMAN)
  • NCBI Gene: 56616
  • HGNC symbol: DIABLO (gene); protein commonly called SMAC
  • Mouse ortholog: Diablo (one-to-one; high sequence identity)
  • Precursor length: 239 amino acids (including N-terminal mitochondrial targeting sequence)
  • Mature length: 184 amino acids (residues 56–239) after MTS cleavage; mature protein runs ~25 kDa 1

Discovery

SMAC/DIABLO was identified independently and simultaneously by two groups in 2000, published back-to-back in Cell:

  • Du et al. 2000 named the protein SMAC (Second Mitochondria-derived Activator of Caspases) and showed it promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition 1.
  • Verhagen et al. 2000 named the same protein DIABLO (Direct IAP-Binding protein with LOw pI) and demonstrated it binds and antagonizes multiple IAP family members 2.

The two names are used interchangeably; DIABLO is the HGNC-approved gene symbol. The protein shares functional ancestry with the Drosophila melanogaster IAP-antagonists Reaper, Hid, and Grim, all of which contain an AVPI-like IAP-binding motif at their mature N-terminus (see below).

Subcellular localization and processing

SMAC/DIABLO is synthesized as a 239 aa cytosolic precursor and traffics to the mitochondrial intermembrane space (IMS) via an N-terminal mitochondrial targeting sequence (MTS). UniProt Q9NR28 annotates two sequential proteolytic cleavage events:

  1. MTS removal (residues 1–55): The N-terminal 55-residue mitochondrial targeting sequence is cleaved upon import, generating the mature form (~184 aa, ~25 kDa). The cleavage site was mapped by N-terminal sequencing of Smac purified from Sf-21 cells: mature protein begins at residue 56 1. The mature N-terminus exposes the Ala-Val-Pro-Ile (AVPI) tetrapeptide, which is the functional IAP-binding arm.
  2. Additional processing (later refinement): Some evidence suggests a further N-terminal trim (e.g., by PARL or a related mitochondrial protease), but this was not established in the 2000 discovery papers. The biologically active species is the ~184 aa form beginning with AVPI.

The key functional unit is the mature ~184 aa form (residues 56–239 of the precursor).

Structure

SMAC/DIABLO forms a homodimer in solution. The 2.2 Å crystal structure (Liu et al. 2000) reveals an arch-shaped homodimer with the two AVPI N-termini positioned on the surface of the dimer, each in principle capable of engaging a separate IAP molecule 3. Important caveat: Liu et al. 2000 showed that XIAP BIR2 and BIR3 exclude each other upon binding to Smac — a single XIAP molecule cannot simultaneously engage both BIR domains with one Smac dimer. The dimer architecture is required for BIR2 binding (monomeric Smac mutants cannot interact with BIR2) but not for BIR3 interaction.

The AVPI motif fits into a conserved shallow groove on XIAP BIR domains (BIR2 and BIR3), mimicking the N-terminal neo-epitope generated by caspase cleavage of many substrates. This structural mimicry is the basis of SMAC mimetic drug design.

Release from mitochondria

SMAC/DIABLO is retained in the IMS under normal conditions. During intrinsic apoptosis:

  1. Pro-apoptotic BAX and/or BAK undergo MOMP-dependent oligomerization and form pores in the outer mitochondrial membrane 45.
  2. SMAC/DIABLO is co-released into the cytosol alongside cytochrome-c.
  3. The timing and stoichiometry of SMAC release closely parallel cytochrome c release, though SMAC must be in its processed mature form to function.

needs-replication — Precise kinetics of SMAC vs. cytochrome c co-release timing have not been independently characterized at single-cell resolution.

IAP antagonism mechanism

The core mechanism, established biochemically by Liu et al. 2000 and refined crystallographically in subsequent studies, involves the mature AVPI motif physically competing with caspase N-terminal segments for XIAP BIR-domain binding:

  • vs. XIAP BIR3: Mature SMAC AVPI competes with caspase-9 for the BIR3 binding groove, relieving XIAP inhibition of caspase-9 3. (The mechanistic detail that XIAP BIR3 sequesters caspase-9 as an inactive monomer and that SMAC displacement restores dimerization-dependent activity is established by subsequent crystallographic work, including Shiozaki 2003, already verified on xiap.)
  • vs. XIAP BIR2 (hook/sinker region): SMAC AVPI also competes at BIR2, where the linker immediately N-terminal to BIR2 inhibits caspase-3/-7 via the L141-containing hook and D148-containing sinker contacts (per Riedl 2001, verified on xiap). SMAC binding to BIR2 releases caspase-3/-7 from XIAP suppression.

Net result: SMAC converts a cell in which XIAP is restraining active caspases into a cell that can complete the caspase cascade and die.

Other IAP family members (cIAP1/BIRC2, cIAP2/BIRC3, BIRC6/apollon) also bind SMAC via their BIR domains, though with different affinities and functional consequences than XIAP.

IAP targetBIR domainFunctional consequence of SMAC binding
XIAP (BIRC4)BIR2Releases caspase-3/-7
XIAP (BIRC4)BIR3Releases caspase-9 monomer; enables dimerization
cIAP1 (BIRC2)BIR3Triggers cIAP1 autoubiquitination + degradation 6
cIAP2 (BIRC3)BIR3Similar to cIAP1
BIRC6/ApollonBIRUncertain; BIRC6 is a very large RING-BIR protein

Knockout phenotype

Smac/Diablo-deficient mice (gene trap and targeted deletion) are viable and grossly normal, with no developmental defects or spontaneous disease under standard housing conditions 7. This was a surprising finding given SMAC’s seemingly essential role in amplifying caspase activation. The interpretation is that SMAC tunes apoptosis sensitivity rather than being strictly required for it — XIAP can be overcome by sufficient apoptosome activity even without SMAC de-inhibition, and compensatory mechanisms (e.g., Omi/HtrA2, which also contains an AVPI-like IAP-binding motif) may partially substitute.

Smac-null cells do show reduced apoptotic responses to some stimuli (particularly those that rely on XIAP-suppression relief), consistent with a sensitizer rather than an obligatory activator role.

no-fulltext-access — Okada 2002 PDF not yet confirmed locally; knockout phenotype details (specific stimuli tested, tissue characterization, lifespan data) not independently verified against primary source.

DimensionStatusNotes
Pathway conserved in humans?yesAVPI motif and XIAP BIR interactions biochemically established in human cells
Phenotype conserved in humans?unknownNo human loss-of-function variant with clear apoptosis phenotype reported
Replicated in humans?in-progressSMAC mimetics entering clinical trials (see below)

Aging relevance and senolytic potential

SMAC mimetics as IAP antagonists

Synthetic mimetics of the AVPI tetrapeptide have been developed as anti-cancer therapeutics. Relevant to aging biology, the same IAP-mediated apoptosis resistance that protects tumor cells from chemotherapy may also protect senescent cells from immune clearance and pharmacological elimination, contributing to senescent cell accumulation — a core aging hallmark.

The mechanistic link: Vince et al. 2007 demonstrated that a SMAC mimetic (“Compound A” — an unnamed small molecule; does NOT refer to named clinical mimetics such as LCL161 or birinapant) kills susceptible tumor cells primarily by targeting cIAP1, not XIAP: Compound A triggers rapid cIAP1 autoubiquitination and proteasomal degradation, which stabilizes RIPK1 at the TNF-R1 complex, activates NF-κB, drives autocrine TNFα production, and ultimately commits cells to caspase-8-dependent apoptosis 6. XIAP levels were largely unaffected and XIAP-knockout MEFs remained sensitive to compound A, confirming XIAP is not the rate-limiting target. Whether this cIAP1-centric mechanism applies specifically to senescent cells is under investigation and has not been tested directly.

Named SMAC mimetics in development or trial:

CompoundPrimary IAP targetCancer indicationSenolytic evidence
Birinapant (TL32711)cIAP1/2 > XIAPHeme malignancies, solid tumorsPreclinical needs-replication
LCL161cIAP1/2 + XIAPMultiple myeloma, solid tumorsPreclinical needs-replication
AT-406 (debio1143)cIAP1/2 + XIAPAML, solid tumorsPreclinical needs-replication

needs-human-replication — All senolytic data for SMAC mimetics are preclinical. No clinical trial has formally tested a SMAC mimetic as a senolytic in an aging or age-related-disease indication.

no-mechanism — It is unclear whether senescent cells depend on XIAP vs. cIAP1 vs. other IAP members for apoptosis resistance; mechanism of IAP upregulation in senescence is not firmly established.

Senescent cell apoptosis resistance

Senescent cells resist apoptosis via the Senescent Cell Anti-Apoptotic Pathway (SCAP), which in different cell types involves upregulation of BCL-2, BCL-xL, BCL-W (as established on bcl-2-family-signaling) and may additionally involve IAP upregulation. SMAC/DIABLO-XIAP antagonism is therefore a plausible but unverified senolytic mechanism.

Turnover and regulation

SMAC/DIABLO is a proteasome substrate; ubiquitination by BIRC6 and BIRC7 (Livin) targets it for degradation, providing a feedback that limits SMAC activity. UniProt Q9NR28 annotates these ubiquitination sites based on experimental evidence.

The protein is constitutively expressed in most tissues and not known to be transcriptionally regulated by aging-relevant pathways. Expression levels are not a strong biomarker of apoptosis competence; what matters is the ratio of SMAC to total IAP at the moment of MOMP.

Pathway membership

Key interactors

  • xiap — primary functional target; BIR2 + BIR3 binding releases caspase-3/-7 and caspase-9
  • caspase-9 — freed from XIAP BIR3 monomer-sequestration by SMAC displacement
  • caspase-3 — freed from XIAP BIR2-linker inhibition (indirectly, via SMAC → XIAP)
  • bax / bak — upstream drivers of MOMP that gate SMAC release
  • cytochrome-c — co-released from IMS during MOMP; parallel activator of apoptosome formation

Limitations and knowledge gaps

  • #gap/needs-replication — Smac/Diablo-null mice are viable; the extent to which Omi/HtrA2 or other AVPI-motif proteins compensate in specific tissues is not fully characterized.
  • #gap/needs-human-replication — No human germline LoF variant with clinical phenotype has been described; the population-genetics impact of SMAC variation on cancer risk or aging trajectory is unknown.
  • #gap/no-mechanism — Mechanism by which senescent cells might upregulate XIAP or other IAPs to suppress SMAC function is unknown.
  • #gap/long-term-unknown — Long-term safety of SMAC mimetics (pan-IAP vs. XIAP-selective) in older adults with high senescent cell burden has not been studied.
  • #gap/needs-replication — Whether bivalent SMAC mimetics acting via cIAP1 (the Vince 2007 mechanism) are the relevant senolytic mechanism, vs. XIAP-selective agents, has not been resolved.

Footnotes

Footnotes

  1. doi:10.1016/s0092-8674(00)00008-8 · Du et al. 2000 (SMAC discovery) · in-vitro + biochemical · model: HeLa S-100 extracts + baculovirus-expressed recombinant Smac; MTS cleavage site confirmed by N-terminal Edman sequencing of Sf-21-expressed mature protein (residue 56) · Cell 102:33–42 · 3,446 citations · archive: locally downloaded — ↩ ↩2 ↩3

  2. doi:10.1016/s0092-8674(00)00009-x · Verhagen et al. 2000 (DIABLO discovery) · in-vitro + biochemical · model: 293T cells + mouse neuronal NT2 cells; co-immunoprecipitation + sucrose-gradient fractionation · Cell 102:43–53 · 2,333 citations · archive: locally downloaded — ↩

  3. doi:10.1038/35022514 · Liu et al. 2000 · in-vitro structural/biochemical · Nature 408:1004–1008 · 854 citations · archive: locally downloaded — ↩ ↩2

  4. See bax — BAX oligomerization and MOMP mechanism ↩

  5. See bak — BAK activation and MOMP (verified, FULL) ↩

  6. doi:10.1016/j.cell.2007.10.037 · Vince et al. 2007 · in-vitro + in-vivo · model: human cell lines + mouse xenograft · Cell 131:682–693 · 1,054 citations · archive: locally downloaded — ↩ ↩2

  7. doi:10.1128/mcb.22.10.3509-3517.2002 · Okada et al. 2002 · in-vivo (Smac/Diablo-null mice) · model: gene-trap KO mice, C57BL/6 background · Mol Cell Biol 22:3509–3517 · 172 citations · archive: PMC download pending after two attempts (PMC:133802); PDF not yet confirmed locally no-fulltext-access ↩

Graph View

Backlinks